Announcement on Resolutions of the 2025 Annual General Meeting
Filed with SSE · · 5 pages · Chinese
Summary by 6ix AI
The meeting approved several key proposals, including the application for a credit facility from a bank and the confirmation of director salaries for the upcoming year. The meeting was conducted in accordance with legal requirements, and the voting results were validated by a witnessing lawyer.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Fangsheng Pharmaceutical Co., Ltd. on 6ix
Earlier from Hunan Fangsheng Pharmaceutical
- Announcement on Proposed Inclusion of Company Products in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance
- Announcement on Obtaining Summary Report of Phase III Clinical Trial for Pediatric Jingxing Anti-tussive Granules in Adults with Acute Tracheobronchitis (Syndrome of Wind-cold Transformation into Heat)
- Announcement on Outline of the 2025 Annual and Q1 2026 Performance Briefing
- 2025 Annual Report
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
Later from Hunan Fangsheng Pharmaceutical
- Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Progress in Drug Marketing Authorization Transfer
- Announcement on Resolutions of the 2nd Extraordinary Meeting of the 6th Board of Directors in 2026
- Announcement on Progress in Transferring Partial Equity of Holding Subsidiaries and Introducing Strategic Investors
Follow Hunan Fangsheng Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Fangsheng Pharmaceutical